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Abstract 
Objective: Olmesartan Medoxomil is a type 1 receptor antagonist an antagonist of type 1 receptor (AT1) of angiotensin 
II (A-II) that inhibits numerous actions of A-II in the renin-angiotensin-aldosterone system (RAAS). A-II is a significant 
and multifunctional peptide involved in the pathophysiology of blood hypertension and for this reason it represents the 
main target in several classes of drugs used to treat and control arterial hypertension, such as angiotensin converting 
enzyme inhibitors (ACE-i), angiotensin receptor blockers (ARB) and renin direct inhibitors. The aim of the study is to 
evaluate whether the two drugs that have as an active principle Olmesartan Medoxomil, with and without the diuretic 
hydrochlorothiazide, are able to determine gingival overgrowth. Study Design: 108 subjects were examined and divided 
into three groups: G1, subjects treated with Olmesartan Medoxomil and hydrochlorothiazide (n=60); G2, subjects 
received only Olmesartan Medoxomil (n=24); G3, control group without pharmacological therapies (n=24). The plaque 
index (IP) and the gingival overgrowth index (OI) were recorded, considering the vertical and horizontal components. 
Results: Vertical overgrowth averaged between 0.17 ± 0.15 (G3) and 0.34 ± 0.26 (G2) showing statistically significant 
differences (p <0.05) compared to the other groups. Horizontal overgrowth ranged from 0.18 ± 0.26 (G3) to 0.49 ± 0.35 
(G2) showing statistically significant differences (p <0.05). Conclusions: antihypertensive agents as Olmesartan 
Medoxomil may result in mild gingival overgrowth in the upper and lower frontal dental elements not related to other 
etiological factors. 
Keywords: Gingival overgrowth, hypertension, angiotensin II, antihypertensive agents. 
INTRODUCTION  
The term gingival overgrowth means excessive growth of the gingival tissue due to an increase in the size 
of the individual cells that compose it [1]. 
Gingival overgrowth appears in both the free and the attached gingiva. It mainly affects the interdental 
papillae in the anterior mandibular portion, affecting the buccal surface and, in lesser extent, palatal and 
lingual surfaces [2]. 
Gingival overgrowth is classified according to the etiology: inflammatory (plaque and calculus deposits), 
gingival fibromatosis (familiar and idiopathic forms), hormones (gingivitis and pregnant epulis), neoplastic 
and, at the end, drug-induced (related to intake of anticonvulsants, calcium antagonists and cyclosporins). 
It is a widely held view that more than 20 drugs prescribed regularly can act as etiological factors in this 
clinical case [3]. Mainly three groups of drugs have been associated with iatrogenic gingival overgrowth. 
Anticonvulsants, particularly diphenyldantoin (phenytoin or dantoin); calcium channel blockers, such as 
nifedipine, a substance used in various cardiovascular pathologies [4, 5]. immunosuppressors such as 
cyclosporine A (CsA), a drug used in the transplanted organ patient for prevention of graft rejection [6]. 
Despite the pharmacological diversity, all three types of drugs, in relation to their mechanism of action, 
act in a similar way at cellular level. In fact, they are able to inhibit the ionic flow of intracellular calcium [7, 
8]. Circumstance that would cause, as a common side effect, overgrowth of the gingival connective tissue. 
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Figire 1: The antihypertensive mechanism of angiotensin receptor blocking. The 
diagram describes the renin-angiotensin-aldosterone system (RAAS) in which 
renal renin release catalyzes the conversion of angiotensinogen into A-I and 
subsequently into A-II from circulating and pulmonary angiotensin converting 
enzymes (ACEs). A-II produces a multitude of physiological effects including 
vasoconstriction, release of aldosterone from the adrenal cortex, and release of 
catecholamines by activation of angiotensin receptors (AT1) at the level of 
smooth muscle tissue vessels. Olmesartan and analogs, blocking the effect of A-
II on AT1, produce anti-hypertensive effect (BP: blood pressure) [9]. 
The renin-angiotensin-aldosterone system (RAAS) plays a key role in 
regulating blood pressure and the pathogenesis of hypertension. It 
consists in an enzymatic cascade: angiotensinogen, produced by liver, 
is converted to angiotensin I (A-I) by renin, secreted by juxtaglomerular 
cells by kidneys. The angiotensin-converting enzyme (ACE) converts A-I 
into A-II (Fig. 1). ACE inhibitor drugs block the formation of A-II, also 
preventing the degradation of bradykinin. The consequent 
accumulation of bradykinin, as well as the substance P and related 
active peptides, can contribute to the development of side effects such 
as cough and angioedema [9]. In addition, ACE inhibitors may block the 
RAAS completely. In vitro studies have shown that angiotensinogen can 
be converted into A-II by dependent non-renin enzymes, such as tissue 
plasminogen activator, cathepsin G, elastase and chymostatin [9]. 
The primary receptors for A-II are AT1 and AT2; the blockage of the 
AT1 receptors consequently triggers an increase in circulating 
angiotensin II levels, with possible overstimulation of the AT2 
receptors. These effects include vasodilation, sodium and water 
retention, cell proliferation and overgrowth [9]. 
▪ At cellular level, A-II modulates cell growth, differentiation and 
apoptosis; the over stimulation of this receptor may favor the 
production of inflammatory cytokines (eg IL-6), the expression of 
adhesion molecules and the consequent recall of inflammatory 
cells, chemotaxis, activation of macrophages, fibroblasts growth 
and the synthesis of extracellular matrix proteins by activating the 
tissue remodeling process [10]. 
▪ At renal level, A-II modulates the growth and synthesis of 
extracellular matrix, determining fibrogenesis and overgrowth of 
renal tubular cells [11]. One of the main targets of A-II in renal 
fibrosis is TGF-β, a pro-fibrotic cytokine; it in fact stimulates its 
synthesis and transcription, and induces specific receptors for 
TGF-β, enhancing fibrogenesis, accumulation of extra-cellular 
matrix, inflammation and apoptosis.11 All this leads to long-term 
instability of renal failure. 
▪ The selective blockade of AT1 and the over-stimulation of AT2 
caused by the angiotensin receptor blockers (ARBs) may result 
positive to have a beneficial effect on mediating vasodilatation 
and controlling hypertension. However, it would appear that in 
the long term, AT2 stimulation could also exert hypertrophic and 
anti-angiogenic influence on cardiovascular tissues. Thus, the 
long-term consequences of ARBs therapy may be less 
advantageous than what was supposed and could even be 
harmful in some circumstances. The potential consequences of 
such effects could include cardiac overgrowth, vascular fibrosis 
and a decrease in vascularization in hypoxic tissues such as 
myocardium [12]. 
In 1996, Yanagisawa and his colleagues studied normotensive rats 
whose AT2 receptor was pharmacologically blocked. This did not have 
any effect on blood pressure, instead rats showed overgrowth and 
fibrosis; this suggests that the effects of A-II can be partly mediated by 
the AT2 receptor. The chronic blockade of AT1 with Losartan lowered 
blood pressure, inducing overgrowth of muscle cells and hyperplasia. 
This study, and many others, suggest both pro-hypertrophic and anti-
hypertrophic effects of AT2 [13]. 
Despite a low content of AT1 and AT2 receptors in the heart, A-II has 
been shown to increase the risk of overgrowth in rat cardiac myocytes; 
this action is then blocked by specific AT1 receptor antagonists [14].  
In vivo studies on animal pointed out A-II as a hypertrophic heart 
agent, despite the emodinamic loading effects. A-II growth 
stimulation’s on myocytes can be primary or secondary to a greater 
synthesis and release of other growth factors by myocytes and non-
myocyte cells.  
The evidence that A-II acts on myocytes to stimulate their growth, 
either directly or through mediation of other factors, was first reported 
in the embryonic mycocytes of chicks [15]. If the AT1 receptor can block 
or reduce the proliferation and cellular overgrowth caused by A-II, the 
intake of Olmesartan Medoxomil could trigger the overgrowth of other 
body areas, including gums. This happens because Olmesartan 
Medoxomil blocks the AT1 receptor.  
The aim of the study is to evaluate whether the two drugs with 
Olmesartan Medoxomil as the active principle both with and without 
diuretic hydrochlorothiazide, are able to determine gingival 
overgrowth. 
MATERIALS AND METHODS 
The study design was prospective observational. Groups were not 
influenced in any way during the process. Their exposure was 
spontaneous and not conditioned by the researcher. For this reason 
the participation of the ethics committee was not necessary. The 
research followed the U.E. guidelines of good clinical practice, in 
accordance to the Helsinki declaration. The experimental purpose of 
the clinical data was disclosed to each patient. 
108 subjects (62 males, 46 females) from the Cardiology Department, 
suffering from hypertension and treated with these drugs were divided 
into three groups: G1 = 60 subjects treated with Olmesartan 
Medoxomil and hydrochlorothiazide (average dosage 20.5 ± 1.51 mg / 
day) (mean age 66 ± 11); G2 = 24 subjects treated with Olmesartan 
Medoxomil (average dosage 21.2 ± 2.2 mg / day) (mean age 63 ± 7); G3 
= 24 healthy subjects not on medication (60± 15).  
Patients in the study were examined at the Odontostomatological 
Clinic at the University Hospital of Trieste from June 2014 to January 
2016. 
Subjects with total edentulism were excluded from the study, as those 
who were taking other drugs that could potentially interfere with 
periodontal tissues such as cyclosporine, nifedipine, calcium channel 
blockers and diphenylantoin. The participation of those who 
underwent hormonal therapy and periodontal surgery in the upper 
(1.3 to 2.3) and lower (3.3 to 4.3) frontal region was also prevented. 
One of the main inclusion criteria was that patients had to have at least 
the elements from 1.3 to 2.3 and 3.3 to 4.3. The teeth notation used is 
the ISO system by WHO. 
The individual periodontal signs of the II (1.3 to 2.3) and V (4.3 to 3.3) 
region were recorded, including the presence of restorations; the 
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plaque index (IP), the presence of plaque on the four surfaces 
(vestibular, mesial, distal, and lingual or palatal) were detected through 
the passage of a PCP12 probe (Hu-Friedy) and the percentage of 
surfaces covered by plaque were evaluated. The gingival overgrowth 
index (OI) was examined considering the vertical [16] and horizontal [17] 
analysis of the gingival increase (Table 1). Applying Seymour’s method, 
the horizontal component of the overgrowth have been assessed. This 
method consists in dividing the upper and lower anterior segments into 
five gingival units, both buccally and lingually and measuring the area 
between two teeth. Furthermore, both vertical and horizontal 
components (expressed in millimeters) have been evaluated.  
Table 1: It’s a representation of the detection method with different 
levels of overgrowth, both horizontal and vertical.  
 Vertical overgrowth Horizontal overgrowth 
Grade 0 Abscence of overgrowth Abscence of overgrowth 
Grade 1 Rounding of marginal gingiva Gingival thickness <2 mm 
Grade 2 Gingival margin covers less than the half 
of the dental crown 
 
Gingival thickness ≥2 mm 
Grade 3 Gingival margin covers more than the 
half of the dental crown 
 
 
 
All data were recorded by a professional dental hygenist from the 
Odontostomatologic Clinic of the University of Trieste. The gingival 
overgrowth’s percentage per patient has been calculated as if follows: 
adding the overgrowth grades of different sites (six sites for the vertical 
overgrowth and ten sites for the horizontal overgrowth), afterwards, 
the result was divided by the total number of sites and it was 
multiplied by 100. The exceeding 30% outcome, suggests the presence 
of gingival overgrowth [18]. (Fig. 2 and Fig. 3). Due to the fact that it 
does not exist a unified method to combine vertical and horizontal 
overgrowth, we decided to use the 30% as cutoff value. 
 
Figure 2: Subject with no sign of total gingival overgrowth (OI<30%) (horizontal 
overgrowth 0; vertical overgrowth 0) who was taking Olmesartan Medoxomil 
and hydrochlorothiazyde for 52 months. 
 
Figure 3: Subject with signs of total gingival overgrowth (OI>30%) (total mean 
horizontal overgrowth 0,6; total mean vertical overgrowth 0,15) who was taking 
Olmesartan Medoxomil and hydrochlorothiazyde for 18 months. 
Statistic analysis 
Continuous variables were described with mean and standard 
deviation while nominal variables were described with frequency. 
Parametric tests were chosen after testing the normality with the 
Shapiro-Wilk test and the variance with the Levene test. Univariate 
ANOVA was used to evaluate differences for IP, horizontal and vertical 
overgrowth, number of restorations and teeth. The non-parametric 
distribution of the OI% data allowed us to use the Kruskall-Wallis test. 
A p-value lower than 0.05 was accepted as statistically significant. 
All the variables taken into consideration were statistically analyzed 
with the SpSS 18.0, statistical software for Mac OS X. 
RESULTS 
Statistically, there were no significant changes with regard to sex, age 
and duration of drug therapy among the groups examined (Table 2). 
 
Table 2: Summary data of the three study groups. 
 Group 1 (G1=Olmesartan Medoxomil  
+ idroclorotiazide) (n=60) 
Group 2 (G2=Olmesartan  
Medoxomil) (n=24) 
Group 3 (G3= control) 
(n=24) 
Significance 
Male ; Female 34;26 17;7 11;13 NS* 
Age (SD years) 66.32 (11.37) 63.38 (7.73) 60.54 (15.49) NS* 
Duration of therapy (SD  months) 42.45 (30.87) 78.50(41.75)  NS* 
Restoration (SD mean) 3.07 (2.81) 2.54 (2.13) 2.29 (2.85) NS° 
IP (SD mean %) 39.13 (24.17) 32.50 (29.16) 32.33 (30.45) NS° 
Number of teeth (SD mean) 11.23 (11.85) 11.29 (1.76) 11.04 (2.20) NS° 
Vertical overgrowth (SD mean expressed in mm) 0.17 (0.30) # 0.34 (0.26) # 0.17 (0.15) # p=0.019 
Horizontal overgrowth (SD mean expressed in mm) 0.33 (0.35) # 0.49 (0.35) # 0.18 (0.26) # p=0.0089 
NS *: not significant (Kruskal-Wallis test p <0.05). NS°: not significant (Unova univaria test). # Test Bonferroni p <0.05. 
 
The frequency of conservative or prosthetic restorations ranged from 
2.29 (G3) to 3.07 (G1) with no statistically significant differences. 
Additionally, the number of teeth and the plaque index did not show 
statistically significant differences (p> 0.05). However, the plaque index 
ranged from 32.33% (G3) to 39.13% (G1) and exceeded the stability 
criteria of periodontal disease. 
Vertical overgrowth averaged between 0.17 ± 0.15 (G3) and 0.34 ± 0.26 
(G2) showing statistically significant differences (p <0.05) compared 
with the other groups. 
Horizontal overgrowth ranged from 0.18 ± 0.26 (G3) to 0.49 ± 0.35 (G2) 
showing statistically significant differences (p <0.05). Comparing the 
  
183 
three groups, it was found that both mean horizontal overgrowth and 
vertical overgrowth showed statistically significant differences <0.05 
(Fig. 4 and 5). 
 
Figure 4: Horizontal overgrowth mean of the three groups (Test Bonferroni 
p<0,05). 
 
Figure 5: Vertical overgrowth mean of the three group (Test Bonferroni p<0,05). 
The subjects affected by gingival overgrowth (OI>30% as cut-off value) 
in G1 were 25 of the 60 overall enlisted patients (41%), those in G2 
were 18 over the 24 enlisted patients (75%) and those in the G3 were 6 
over the 24 total patients (25%). From the statistical analysis, 
significative differences between G1 and G2 as compared to G3 may be 
recorded. (Fig. 6.) 
 
Figure 6: Distribution of gingival overgrowth within groups. 
DISCUSSION 
Currently the AT1 receptor antagonist drugs are widely used to control 
blood hypertension, the most frequent cardiovascular disease. They 
have few side effects such as cough, gastrointestinal disorders, 
headache and dizziness. 
The aim of our study is to evaluate whether two drugs with active 
agents based on Olmesartan Medoxomil, one of which with diuretic 
hydrochlorothiazide, could cause gingival overgrowth among its side 
effects. 
The Mire study conducted in 2005 showed that the binding of A-II with 
the AT1 receptor can cause vasoconstriction, water and sodium 
retention, cell proliferation and overgrowth. The latter co uld therefore 
also occur at the gingival level. 
Unlike other drugs, with CsA, which have shown gingival overgrowth 
influenced by age, in both gender and for dose and duration of therapy 
[19, 20], no statistically significant difference from the demographic point 
of view, has emerged from our study.  
Furthermore, in this study the presence of local irritative factors such 
as conservative or prosthetic restorations and bacterial plaque are not 
determinative of significant changes in the degree of gingival 
overgrowth. Even in subjects using CsA it has been shown that optimal 
plaque control and removal of local irritants do not prevent gingival 
increase but may reduce the severity of lesions.18,20 
The antihypertensive action of Olmesartan is increased by the addition 
of hydrochlorothiazide. It was observed that the combination of 
Olmesartan with diuretic agent leads to a greater antihypertensive 
efficacy and an increase in the percentage of those with optimal blood 
pressure control. Furthermore, compared to single medication therapy, 
it reduces the frequency and severity of adverse circumstances and 
increases the patients’ compliance. We observed that the use of 
Olmesartan alone showed greater vertical and horizontal overgrowth 
than subjects taking Olmesartan associated with hydrochlorothiazide, 
indicating that this side effect is also significantly reduced. Probably, 
the ability of hydrochlorothiazide to eliminate sodium and water has 
an anti-hypertrophic effect even at the peripheral cellular level. 
Gingival overgrowth seems to be a collateral effect that accompanies 
these medications. All subjects presenting gingival overgrowth (OI> 
30%) were reported at the Pharmacovigilance Committee of the 
University Hospital of Trieste.  
The gingival overgrowth grading system had some limitations 
considering that there is no available grading system that considers 
both the vertical and the horizontal components in a univocal way. 
Nonetheless, the venture made between those two systems seemed to 
work. 
Considering the practical results the study has achieved, it would be 
interesting to expand the study and deepen the issue, involving other 
medical centers also outside of our country 
The clinical implication that our experience suggests is to establish a 
connection with the patient physician so to evaluate possible 
alternatives to the drugs prescribed, in order to reduce or better avoid 
the the possbile side effects described in our study. 
This study suggests that examined subjects who used Olmesartan 
Medoxomil show a mild gingival overgrowth in the upper and lower 
frontal teeth; this condition is unrelated to plaque index and the 
presence of local irritative factors.  
Gingival overgrowth is a risk factor for plaque accumulation and 
periodontal pocket formation and for the subsequent progression of 
periodontal disease. To prevent this, in patiens taking these 
medications, regular check-ups would be useful.  
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